Arecor granted first US patent for insulin formulations

Biopharmaceutical company Arecor Therapeutics announced on Wednesday that the United States Patent and Trademark Office has granted a patent protecting novel formulations of its proprietary insulin products, ‘AT247’ and ‘AT278’.

The AIM-traded firm said it was investing in building a “strong” patent portfolio to protect the ‘Arestat’ technology platform and its proprietary pipeline products.

Its intellectual property portfolio currently consisted of 36 patent families, including more than 50 granted patents in Europe, the US and in other key territories.

As part of its strategy, Arecor said it had “robust” intellectual property directed to the novel insulin compositions, protecting different aspects of AT247 and AT278 formulations, as well as their specific properties and methods of use.

The company said its strategy was to generate a “fortress” of both narrow and broad interrelated intellectual property rights covering the features of the products.

US11278624 was the first granted US patent within its insulin intellectual property strategy.

“Arecor's novel insulin products, based on a combination of existing insulin analogues and our highly innovative formulation science, have potential to improve convenience, compliance and enable more effective management of blood glucose for people living with type 1 and type 2 diabetes,” said chief scientific officer Dr Jan Jezek.

“As the clinical validation of the superiority of these products compared to current gold standard prandial insulins continues, we are also advancing the intellectual property protection for these products.

“This recently granted US patent, the first within the group's comprehensive insulin IP strategy, is a significant milestone, and we will continue to strengthen our IP portfolio with additional patent applications already in progress.”

At 1116 GMT, shares in Aercor Therapeutics were up 8.17% at 397p.